Universiteit van Amsterdam, Amsterdam, The Netherlands.
Dis Colon Rectum. 2011 Feb;54(2):171-5. doi: 10.1007/DCR.0b013e3181fd677d.
Neoadjuvant chemotherapy decreases total lymph nodes harvested and possibly affects lymph node staging after total mesorectal excision in patients with rectal cancer.
This study aimed to compare staging by lymph node ratio with staging by absolute number of positive lymph nodes.
This study is a retrospective cohort review.
: A tertiary care referral center was the setting for this investigation.
A total of 281 consecutive patients who underwent neoadjuvant chemoradiation and total mesorectal excision after histologically confirmed rectal cancer between January 1, 1998 and December 31, 2008 were included in this study.
Lymph node ratio is the number of positive lymph nodes divided by the total number of lymph nodes within one sample. Risk categories of low (0 to < 0.09); medium (0.09 to < 0.36); and high (≥ 0.36) for lymph node ratio were chosen by significance with the use of Cox proportional hazards models. These categories were then used in a reclassification table and compared with positive lymph node stage: low (0 positive nodes), medium (1-3 nodes), and high (> 3) by 5-year mortality rates.
The majority (87%) of patients were concordant in risk assessment. Thirty patients were downstaged to lower risk lymph node ratio categories without showing actual lower mortality rates. Seven patients were upstaged to a high-risk lymph node ratio category with a supporting higher 5-year mortality rate. When limiting the analysis to those with fewer than 12 nodes, 136 (95%) patients were concordant in risk assessment; all 30 incorrectly downstaged patients were removed, but the 7 correctly upstaged patients remained.
Patients who undergo neoadjuvant chemoradiation before rectal cancer surgery frequently have fewer than 12 lymph nodes harvested despite maintaining vigorous surgical standards. Lymph node ratios may provide excellent prognostic value and are possibly a better independent staging method than absolute positive lymph node counts when less than 12 lymph nodes are harvested after neoadjuvant treatment.
新辅助化疗会减少所采集的总淋巴结数量,并可能影响直肠癌患者接受全直肠系膜切除术后的淋巴结分期。
本研究旨在比较淋巴结比率分期与阳性淋巴结绝对数量分期。
本研究为回顾性队列研究。
本研究在一家三级医疗中心进行。
共纳入 281 例 1998 年 1 月 1 日至 2008 年 12 月 31 日期间经组织学证实的直肠癌患者,这些患者均接受了新辅助放化疗和全直肠系膜切除术。
淋巴结比率是指一个样本中阳性淋巴结的数量与总淋巴结数量的比值。通过 Cox 比例风险模型的显著性选择低(0 至 <0.09)、中(0.09 至 <0.36)和高(≥0.36)淋巴结比率风险类别。然后,将这些类别用于再分类表,并与阳性淋巴结分期(0 个阳性淋巴结、1-3 个淋巴结和>3 个)比较 5 年死亡率。
大多数(87%)患者的风险评估一致。30 例患者因淋巴结比率分期较低而降级为风险较低的类别,但实际死亡率并未降低。7 例患者因淋巴结比率分期较高而升级为风险较高的类别,且支持更高的 5 年死亡率。当将分析限制在淋巴结少于 12 个的患者时,136 例(95%)患者的风险评估一致;所有 30 例错误降级的患者被排除,但 7 例正确升级的患者仍然存在。
尽管保持了积极的手术标准,但接受直肠癌术前新辅助放化疗的患者经常采集到的淋巴结少于 12 个。当新辅助治疗后采集的淋巴结少于 12 个时,淋巴结比率可能提供极好的预后价值,并且可能是比阳性淋巴结绝对数量更好的独立分期方法。